Isoflurane
Forane (isoflurane) is a small molecule pharmaceutical. Isoflurane was first approved as Forane on 1982-01-01. It is used to treat depressive disorder and status asthmaticus in the USA. It is known to target potassium channel subfamily K member 16, potassium channel subfamily K member 3, potassium channel subfamily K member 2, and transient receptor potential cation channel subfamily A member 1.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Forane (generic drugs available since 1994-09-30)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Isoflurane
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
FORANE | Baxter | N-017624 RX | 1982-01-01 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
forane | New Drug Application | 2017-04-27 |
isoflurane | ANDA | 2023-02-16 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
depressive disorder | EFO_1002014 | D003866 | F32.A |
status asthmaticus | — | D013224 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
76 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Delirium | D003693 | R41.0 | — | — | — | 2 | 1 | 3 | |
Postoperative pain | D010149 | G89.18 | — | — | — | 1 | 1 | 2 | |
Hypotension | D007022 | EFO_0005251 | I95 | — | — | — | 1 | 1 | 2 |
Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | — | 1 | 1 | 2 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | 2 | — | 2 |
Coronary disease | D003327 | — | — | — | 1 | 1 | 2 | ||
Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | 1 | — | 1 | — | 2 |
Vomiting | D014839 | HP_0002013 | R11.1 | — | — | — | 1 | — | 1 |
Nausea | D009325 | HP_0002018 | R11.0 | — | — | — | 1 | — | 1 |
Intestinal pseudo-obstruction | D007418 | EFO_1000988 | K56.0 | — | — | — | 1 | — | 1 |
Show 15 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Anesthesia | D000758 | 1 | — | 1 | — | 1 | 3 | ||
Aortic valve insufficiency | D001022 | EFO_0007148 | 1 | — | 1 | — | — | 2 | |
Mitral valve insufficiency | D008944 | HP_0001653 | 1 | — | 1 | — | — | 2 | |
Inguinal hernia | D006552 | HP_0000023 | K40 | — | — | 1 | — | — | 1 |
Hydrocephalus | D006849 | HP_0000238 | G91 | — | — | 1 | — | — | 1 |
Covid-19 | D000086382 | U07.1 | — | — | 1 | — | — | 1 | |
Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 2 | — | — | — | 2 |
Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 2 | — | — | — | 2 |
Treatment-resistant depressive disorder | D061218 | — | 1 | — | — | — | 1 | ||
Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cardiopulmonary bypass | D002315 | — | — | — | — | 2 | 2 | ||
Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | — | — | — | 1 | 1 | |
Dementia | D003704 | F03 | — | — | — | — | 1 | 1 | |
Laryngeal neoplasms | D007822 | EFO_0003817 | C32 | — | — | — | — | 1 | 1 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | — | 1 | 1 |
Local anesthesia | D000772 | — | — | — | — | 1 | 1 | ||
Congenital heart defects | D006330 | HP_0001627 | Q24.9 | — | — | — | — | 1 | 1 |
Neurodevelopmental disorders | D065886 | F89 | — | — | — | — | 1 | 1 | |
Colonic neoplasms | D003110 | C18 | — | — | — | — | 1 | 1 | |
Anesthesia recovery period | D000762 | — | — | — | — | 1 | 1 |
Show 16 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | ISOFLURANE |
INN | isoflurane |
Description | Isoflurane is an organofluorine compound. It has a role as an inhalation anaesthetic. It is functionally related to a methoxyethane. |
Classification | Small molecule |
Drug class | general inhalation anesthetics (halogenated alkane derivatives) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | FC(F)OC(Cl)C(F)(F)F |
Identifiers
PDB | — |
CAS-ID | 26675-46-7 |
RxCUI | 6026 |
ChEMBL ID | CHEMBL1256 |
ChEBI ID | 6015 |
PubChem CID | 3763 |
DrugBank | DB00753 |
UNII ID | CYS9AKD70P (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
KCNK16
KCNK16
KCNK3
KCNK3
KCNK2
KCNK2
TRPA1
TRPA1
Organism
Homo sapiens
Gene name
KCNK16
Gene synonyms
TALK1
NCBI Gene ID
Protein name
potassium channel subfamily K member 16
Protein synonyms
2P domain potassium channel Talk-1, pancreatic potassium channel Talk-1, potassium channel, subfamily K, member 16, potassium channel, two pore domain subfamily K, member 16, TALK-1, TWIK-related alkaline pH-activated K(+) channel 1
Uniprot ID
Mouse ortholog
Kcnk16 (74571)
potassium channel, subfamily K, member 16 (G5E845)
Variants
Clinical Variant
Identifier | Target mutation | Effect | Evaluation | Status |
---|---|---|---|---|
VCV000575733 | CACNA1S, 520C>T, Arg174Trp | drug response | 2021-03-24 | 1A |
VCV000017626 | CACNA1S, 3257G>A, Arg1086His | drug response | 2021-03-24 | 1A |
VCV000012984 | RYR1, 14545G>A, Val4849Ile | drug response | 2021-03-24 | 1A |
VCV000012972 | RYR1, 7373G>A, Arg2458His | drug response | 2021-03-24 | 1A |
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 160,318 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,892 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more